lawmakers should revisit that idea when lepage is no longer in office next year.
.
orchid pharma faces liquidation as lenders reject resolution plan
.
5 / 5
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
all programs
.
viewpoint: china has the upper hand in cancer cell therapy